No Data
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $8
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $5
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Lowers Price Target to $5
Express News | Pyxis Oncology, Inc. : H.c. Wainwright Cuts Target Price to $5 From $7